D-0493-2017 Class II Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-0493-2017 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Jan 27, 2017 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled The recall status is terminated (terminated Mar 15, 2019). Affected quantity: 58 UD100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each).

Recall details

Product Type
Drugs
Report Date
Mar 15, 2017
Initiation Date
Jan 27, 2017
Termination Date
Mar 15, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
58 UD100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each)

Product description

Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV ---NDC 51079-088-20

Reason for recall

Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled

Distribution pattern

Nationwide

Code information

Batch #3083289; Exp. Date 12/2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0493-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0493-2017. Report a data issue: hello@regdatalab.com.